LIDDS AB (publ) (STO:LIDDS)

Market Cap	3.36M -81.5%
Revenue (ttm)	n/a
Net Income	-5.58M
EPS	-0.03
Shares Out	136.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,794
Average Volume	353,784
Open	0.0246
Previous Close	0.0246
Day's Range	0.0246 - 0.0246
52-Week Range	0.0100 - 0.2150
Beta	-0.27
RSI	49.90
Earnings Date	Mar 26, 2026

About LIDDS AB

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: LIDDS